DNER and neoplasm: Consistent with this superenhancer driving MYC transcription, JQ1 treatment preferentially reduced c-MYC expression in CCAT1-expressing cells; therefore, CCAT1 is a superenhancer template RNA that may serve as a predictive biomarker to identify tumors that utilize BET-mediated MYC transcription for tumor growth.